# US 2012/0258889 A1 · siRNA Targeting Kinase Insert Domain Receptor (KDR)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0258889 A1
- Document ID: US20120258889A1
- Status: Published application
- Kind: A1
- Application number: 13/524,015
- Filed: 2012-06-15
- Published: 2012-10-11
- Earliest claimed: 2002-11-14
- Assignees: Dharmacon, Inc.
- Inventors: Anastasia Khvorova; Angela Reynolds; Devin Leake; William Marshall; Steven Read; Stephen Scaringe
- Web page: https://patentgrep.com/patent/US20120258889A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2320/11: for the determination of target sites, i.e. of active nucleic acids
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for KDR.

## Claims

### Claim 1

An siRNA molecule, wherein said siRNA molecule consists of: (a) a duplex region; and (b) either no overhang regions or at least one overhang region, wherein each overhang region contains six or fewer nucleotides, wherein the duplex region consists of a sense region and an antisense region, wherein said sense region and said antisense region are each 19-30 nucleotides in length and said antisense region comprises a sequence that is the complement of a sequence selected from the group consisting of SEQ ID NO: 438-463, 465-556 and 558-622.

### Claim 2 (depends on 1)

The siRNA molecule of claim 1, wherein said antisense region and said sense region are each 19-25 nucleotides in length.

### Claim 3 (depends on 2)

The siRNA molecule of claim 2, wherein said antisense region and said sense region are each 19 nucleotides in length.

### Claim 4 (depends on 1)

The siRNA molecule of claim 1, wherein said siRNA molecule has at least one overhang region.

### Claim 5 (depends on 1)

The siRNA molecule of claim 1, wherein said siRNA molecule has no overhang regions.

### Claim 6 (depends on 2)

The siRNA molecule of claim 2, wherein said siRNA molecule has at least one overhang region.

### Claim 7 (depends on 2)

The siRNA molecule of claim 2, wherein said siRNA molecule has no overhang regions.

### Claim 8 (depends on 3)

The siRNA molecule of claim 3, wherein said siRNA molecule has at least one overhang region.

### Claim 9 (depends on 3)

The siRNA molecule of claim 3, wherein said siRNA molecule has no overhang regions.

### Claim 10

A chemically synthesized double stranded siRNA molecule, wherein:
(a) each strand of said double stranded siRNA molecule is between 19 and 30 nucleotides in length; and
(b) one strand of said siRNA molecule comprises a sequence that is the complement of a sequence selected from the group consisting of SEQ ID NO: 438-463, 465-556 and 558-622.

### Claim 11 (depends on 10)

The chemically synthesized double stranded siRNA molecule of claim 10, wherein each strand of said siRNA molecule is 19 nucleotides in length.

### Claim 12 (depends on 11)

The chemically synthesized double stranded siRNA molecule of claim 11 wherein each strand of said siRNA molecule is 19-25 nucleotides in length.

### Claim 13 (depends on 1)

A pool of at least two siRNAs, wherein said pool comprises a first siRNA and a second siRNA, wherein said first siRNA is the siRNA molecule of claim 1, wherein the duplex region of said first siRNA is a first duplex region and said second siRNA consists of a second duplex region and either no overhang regions or at least one overhang region, wherein each overhang region contains six or fewer nucleotides, wherein the second duplex region of said second siRNA consists of a sense region and an antisense region, wherein said sense region and said antisense region of said second siRNA are each 19-30 nucleotides in length and said antisense region of said second duplex region comprises a sequence that is the complement of a sequence selected from the group consisting of SEQ ID NO: 438-463, 465-556 and 558-622.

### Claim 14 (depends on 13)

The pool of claim 13, wherein said first siRNA and said second siRNA each have no overhang regions.

### Claim 15 (depends on 13)

The pool of claim 13, wherein said sense region and said antisense region of said first siRNA and said sense region and said antisense region of said second siRNA are each 19-25 nucleotides in length.

### Claim 16 (depends on 15)

The pool of claim 15, wherein said sense region and said antisense region of said first siRNA and said sense region and said antisense region of said second siRNA are each 19 nucleotides in length.

### Claim 17 (depends on 16)

The pool of claim 16, wherein said first siRNA contains no overhang regions.

### Claim 18 (depends on 16)

The pool of claim 16, wherein the second siRNA contains no overhang regions.

### Claim 19 (depends on 16)

The pool of claim 16, wherein the first siRNA contains at least one overhang region.

### Claim 20 (depends on 16)

The pool of claim 16, wherein the second siRNA contains at least one overhang region.
